While the cannabis industry in the US has only recently found its big break, medical marijuana research and development has already been well underway for more than a decade now. The UK-based GW Pharmaceuticals, PLC is one of the companies that have been established in this field in the 1990s.
GW Pharmaceuticals is a biopharmaceutical company that focuses on developing cannabis medications, especially for pain management. Two of its biggest endeavors are on the drugs Sativex and Epidiolex.
Sativex is an indicated treatment for multiple sclerosis (MS) spasticity and for cancer pain. Its two principal components are the cannabis-derived substances cannabidiol (CBD) and delta-9 tetrahydrocannabinol (THC). This medication is approved/pending approval in 24 countries including the US, and has licensing agreements with various pharmaceutical giants like Bayer Healthcare and Novartis.
Meanwhile, Epidiolex is the company’s proprietary product candidate currently in an orphan clinical program. With CBD as its active ingredient, the drug is for the treatment of an infantile-onset drug-resistant syndrome of epilepsy called Dravet syndrome.
Aside from these, GW Pharma is also working on other projects, such as the development of another cannabis compound called cannabidivarin (CBDV) for epilepsy.
GW Pharmaceuticals was founded in 1998 by biotech doctors and entrepreneurs Geoffrey Guy and Brian Whittle. It quickly gained support as official investigations in the UK concluded in favor of the potential therapeutic value of cannabis.
Today, the company is being traded in both the NASDAQ Global Market (as GWPH) and London’s Alternative Investment Market (as GWP). Its market cap is pegged at USD 1.65 B, one of the biggest in this Green Rush. Key executives in the company include Dr. Geoffrey Guy, Executive Chairman; Justin D. Gover, CEO; Adam David George, CFO; Christopher John Tovey, COO; and Dr. Stephen Wright, R&D Director.
GW Pharmaceuticals, PLC
Porton Down Science Park
Yahoo! Finance: GWPH News
Latest Financial News for GWPH